Successful promissory note (Schuldschein) placement

Ingelheim/Germany, 09 July 2009 - The pharmaceutical company Boehringer Ingelheim has successfully placed a promissory note (Schuldschein) with a volume of EUR 900 million and maturities of 5, 7 and 10 years.

Due to great investor demand, the originally foreseen emission volume was substantially oversubscribed. In addition, the margin was set at the lower end of the marketing spread. Joint lead managers for the placement were the banks - Helaba, HSBC/Trinkaus und LBBW.

In the currently difficult financial markets, but with historically low interest rate levels, Boehringer Ingelheim thereby secures itself favourable financing terms and achieves a diversification of its funding sources with further institutional investors.

With its good earnings position, also in times of financial and economic crisis, and its sound capital structure, Boehringer Ingelheim is a company sought after by institutional investors that seek safe and long-term investment opportunities.

The funds will stock up liquidity and increase the group’s financial and entrepreneurial flexibility.

Background information about the promissory note

• The debut promissory note emission was three times over subscribed
• The investor base was expanded by some 100 investors in Germany and abroad
• Strong investor interest in the long-term tranches in 7 and 10-year maturities
• Pricing at the lowest end of the marketing spread
• Largest corporate promissory note since Lehman’s bankruptcy
• The largest corporate promissory note (after BMW and Siemens - both before Lehman’s bankruptcy)
• Given the difficult and volatile capital market environment, this is a particular success which underlines the good standing of Boehringer Ingelheim on the capital market.

Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees.

Since it was founded in 1885, the independent, family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of €11.6 billion. The company invested one fifth of net sales in its largest business segment Prescription Medicines in the research and development of new medicines.